BJERKHOLT ERIC — SEC Form 4 filings
SEC reporting owner CIK 1197350. 31 Form 4 filings on record with FilingPulse; latest filed 2026-09-15.
Transaction summary — filings shown
Covers all 31 filings on record, filed 2024-01-25 to 2026-09-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 4,000 shares, $101,200 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 16 legs across 11 filings — 93,737 shares, $4,379,005 total (shares × price as filed on priced legs).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: sale of 9,943 shares @ $98.37 ($978,093) in Mirum Pharmaceuticals, Inc., filed 2026-09-15.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | CHIEF FINANCIAL OFFICER | 18 | 2 legs · 4,000 sh · $101,200 | 14 legs · 53,283 sh · $4,290,125 | 27 |
| CERUS CORP (CERS) | Director | 5 | — | 2 legs · 40,454 sh · $88,880 | 3 |
| Metagenomi Therapeutics, Inc. (MGX) | Director | 3 | — | — | 3 |
| Surrozen, Inc./DE (SRZN) | Director | 3 | — | — | 3 |
| CalciMedica, Inc. (CALC) | Director | 2 | — | — | 2 |
Form 4 filings — BJERKHOLT ERIC
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-15 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,333 · Sale (S): 9,943 @ $98.37 · Option exercise (M): 18,333 (derivative) @ $0 | EDGAR |
| 2026-08-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 6,001 @ $99.90 | EDGAR |
| 2026-07-08 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 3,124 @ $121.67 · Sale (S): 1,048 @ $122.43 · Sale (S): 528 @ $123.84 · Sale (S): 300 @ $124.94 | EDGAR |
| 2026-06-11 | 4 | CERUS CORP (CERS) | Sale (S): 20,454 @ $2.60 | EDGAR |
| 2026-06-11 | 4 | Metagenomi Therapeutics, Inc. (MGX) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 2,258 @ $92.84 · Sale (S): 1,175 @ $93.95 · Sale (S): 1,567 @ $95.12 · Option exercise (M): 2,393 @ $26.49 · Option exercise (M): 2,393 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | CERUS CORP (CERS) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2026-05-14 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 5,550 (derivative) @ $0 | EDGAR |
| 2026-03-17 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 13,334 · Sale (S): 7,287 @ $91.98 · Option exercise (M): 13,334 (derivative) @ $0 | EDGAR |
| 2026-01-30 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 18,140 (derivative) @ $0 · Grant/award (A): 11,760 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-01-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 2,667 · Sale (S): 1,053 @ $96.19 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2026-01-23 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 3,334 · Sale (S): 1,421 @ $93.33 · Option exercise (M): 3,334 (derivative) @ $0 | EDGAR |
| 2025-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,333 · Sale (S): 9,578 @ $76.01 · Option exercise (M): 18,333 (derivative) @ $0 | EDGAR |
| 2025-08-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Sale (S): 8,000 · Option exercise (M): 2,954 @ $26.49 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 8,572 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | CERUS CORP (CERS) | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-05-15 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2025-01-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 2,667 · Option exercise (M): 2,667 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 40,000 (derivative) @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-12-16 | 4 | CERUS CORP (CERS) | Sale (S): 20,000 @ $1.78 | EDGAR |
| 2024-11-14 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 475 @ $21.05 | EDGAR |
| 2024-09-12 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Option exercise (M): 18,334 · Option exercise (M): 18,334 (derivative) @ $0 | EDGAR |
| 2024-08-28 | 4 | CalciMedica, Inc. (CALC) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-06 | 4 | CERUS CORP (CERS) | Grant/award (A): 40,000 @ $5 | EDGAR |
| 2024-06-06 | 4 | Surrozen, Inc./DE (SRZN) | Grant/award (A): 1,333 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 470 @ $21.05 | EDGAR |
| 2024-04-22 | 4 | CalciMedica, Inc. (CALC) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-03-27 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Purchase (P): 2,000 @ $24.80 | EDGAR |
| 2024-03-18 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Purchase (P): 2,000 @ $25.80 | EDGAR |
| 2024-01-25 | 4 | Mirum Pharmaceuticals, Inc. (MIRM) | Grant/award (A): 32,000 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1197350 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →